Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies
Top Cited Papers
- 21 February 2013
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (3), 333-337
- https://doi.org/10.1111/jdv.12106
Abstract
Multiple metrics evaluate the efficacy of psoriasis treatment, but interestingly, the correlation between the mostly widely used clinical trial efficacy end point, the physician-rendered Psoriasis Area Severity Index PASI score and, the most widely used quality of life metric, the Dermatology Life Quality Index DLQI, is not always high. To perform a systematic review to determine PASI to DLQI correlation. RCTs of biological agents for the treatment of moderate-to-severe psoriasis were reviewed in accordance with PRISMA guidelines. The mean percentage PASI improvement and change in mean DLQI values were recorded and compared for treatment groups from baseline to 10-16 weeks of therapy. A search of the literature yielded 155 sources, of which 13 RCTs met inclusion and exclusion criteria. Percentage of PASI improvement from baseline correlates with DLQI changes with an r(2) value of 0.80 from baseline through weeks 10-16. When grouped by mean percentage reduction in PASI, agents demonstrating >75% mean reduction in PASI demonstrated a mean DLQI improvement over agents that achieved <75%-50% mean reduction in PASI or <50% mean reduction in PASI [minimal clinically important difference (MCID) 3.2]. In addition, a reduction in mean PASI of at least 75%, predicted a mean movement from DLQI band 3 to DLQI band 1, in all nine treatment arms demonstrating such efficacy. Mean PASI and DLQI correlate predictably in patients with chronic moderate-to-severe plaque psoriasis undergoing treatment with biological agents. A reduction in PASI of at least 75% can translate to significant quality-of-life improvement in patients treated with these therapies.Keywords
This publication has 44 references indexed in Scilit:
- Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatmentEuropean Journal of Dermatology, 2010
- Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in GermanyDermatology, 2008
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension studyJournal of the American Academy of Dermatology, 2006
- CLinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trialBritish Journal of Dermatology, 2006
- Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trialJournal of the American Academy of Dermatology, 2005
- Effects of Alefacept on Health-Related Quality of Life in Patients with PsoriasisAmerican Journal of Clinical Dermatology, 2003
- Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T LymphocytesThe New England Journal of Medicine, 2001
- Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporinBritish Journal of Dermatology, 2001
- The contribution of perceptions of stigmatisation to disability in patients with psoriasisJournal of Psychosomatic Research, 2001
- The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatizationPhysiology & Behavior, 2000